Seclidemstat

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

Seclidemstat (SP-2577) is an experimental cancer drug. It targets LSD1 (also known as KDM1A), an enzyme that helps regulate which genes are turned on or off in cells. Seclidemstat is a non-covalent, small-molecule inhibitor that blocks both the enzyme’s activity and its role as a building block in gene-silencing complexes like CoREST. By doing this, it reshapes gene expression in cancer cells, which can slow tumor growth and may help the immune system recognize and attack the cancer.

Seclidemstat is being studied in clinical trials to assess its safety and potential to treat cancers such as Ewing sarcoma, SWI/SNF-mutated ovarian cancers, and other advanced solid tumors. Researchers are looking at its anticancer effects and whether it can modulate the tumor’s immune environment. As with other LSD1 inhibitors, achieving a good balance between effectiveness and safety in early trials remains a challenge.